Top View
- Roche Vows to Keep Genentech Culture
- Vertex Pharmaceuticals Incorporated
- A First-In-Human Phase I Study of the OX40 Agonist GSK3174998 (GSK998) +/- Pembrolizumab in Patients (Pts) with Selected Advanced Solid Tumors (ENGAGE-1)
- 1996 Annual-Report.Pdf
- Amgen and Genentech Settle Patent Dispute
- Amgen and Genentech Sign License Agreements for Antibody Patents
- Integrating Peripheral Biomarker Analyses From
- Vertex Pharmaceuticals Incorporated
- Prescriber Service Form SUBMIT ONLY REQUESTED DOCUMENTS Required Field (*)
- Genentech and Biogen Idec Have Filed for a Re-Hearing of U.S. Court of Appeals Decision in the Arzerra Patent Infringement Case
- Tanox Is a Biotechnology Company Specializing in the Discovery and Development of Biotherapeutics Utilizing Monoclonal Antibody Technology
- 10-17-09 Rituxan RA CRL Press Release FINAL
- The ASCO Post Editor Conflict of Interest Disclosures
- Faculty Disclosures
- Genentech, Inc
- ALPINE KEY ELIGIBILITY CRITERIA • Bruton Tyrosine Kinase (BTK) Plays a Critical Role in B‑Cell Receptor Signaling, Which Mediates B‑Cell Table 1
- TECENTRIQ Prescribing Information
- Option to Develop Exelixis Compound Exercised by Genentech
- Faculty Disclosures
- Genentech Business Events 19991999 Andand Earlyearly 20002000
- CFRI's Weekly Summary of News & Events for Our CF Community!
- 2019 Genitourinary Cancers Symposium: Presentation Information Oral Abstract Session C Thomas Powles, MD, Phd, FCRP Saturday, February 16, 2019: 2:00-2:10 P.M
- Managing Costs and Care with Biosimilars
- Genentech Commits to Ophthalmology
- David I. Gindler Partner
- 2021 New Drugs in Oncology Seminar Planning Committee All Relationships Are Considered Compensated
- In the United States District Court for the District of Delaware
- Retina Update: the 10Th Annual J
- Silent Treatment: How Genentech, Novartis Stifled a Promising Drug
- Disclosures and Contributions
- Answer, Affirmative Defenses, and Counterclaims
- CE in the Biotechnology & Pharmaceutical Industries: 22
- Exelixis Signs Co-Development Agreement with Genentech for Small Molecule Oncology Compound
- Member List (PDF)
- Biotech's Roots
- Wyeth's R&D Rationalisation Confirms a New Trend in Research
- Faculty Disclosures
- 2000 Annual-Report.Pdf
- Faculty Disclosures
- Disclosure of Financial Relationships April 10-15 • May 17-21
- Auditor Disclosure Data.Xlsx
- Avelumab (Anti-PD-L1)
- After Lull in Biosimilar IP Litigation, 2021 Could Bring Influx by Joshua Whitehill and Jay Deshmukh (January 7, 2021, 5:35 PM EST)
- CFRI's Weekly Summary of News
- William Young Joins Vertex Board of Directors
- ERIVEDGE Prescribing Information
- Call for Grants Notification (CGN): 2020 Health Equity Innovations Fund
- 1 United States District Court for the District Of
- View the Disclosures for the 2020 Cancer Communications Committee
- 2020 02 11-Genentech-V-Amgen
- A First-In-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors
- COVID-19 Vaccine Failure in a Patient with Multiple Sclerosis on Ocrelizumab
- RITUXAN Prescribing Information
- Joint Status Report
- Proxy Statement 2021
- In the United States District Court for the District of Delaware
- Genentech Pfizer Novartis
- Our Commitment to Diversity & Inclusion
- Specialty Pharmaceutical Distribution Product Portfolio: September 2021
- AASLD Faculty Disclosures.Xlsx
- Presenter Financial Disclosures for AAO 2019
- 1 Retreatment with Telaprevir Combination Therapy in Hepatitis C
- Volunteer Disclosure Report
- 2019 Cancer Communications Committee
- Efficacy of Aducanumab
- Williamson V. Genentech -- Second Amended Class Action Complaint
- Mutanome Draws Genentech Deal
- Roche/Genentech Royalties